These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 9482510

  • 21. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Walker GA, Mac Hannaford JC.
    Fundam Clin Pharmacol; 1995; 9(4):387-94. PubMed ID: 8566940
    [Abstract] [Full Text] [Related]

  • 22. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S, Pieragalli D, Acciavatti A, Del Bigo C, Galigani C, Ralli L, Guerrini M, Di Perri T.
    J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
    [No Abstract] [Full Text] [Related]

  • 23. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM, Lepore R.
    Clin Ter; 1990 Nov 30; 135(4):273-81. PubMed ID: 2150026
    [Abstract] [Full Text] [Related]

  • 24. The effects of prostaglandin E-1 in patients with intermittent claudication.
    Milio G, Coppola G, Novo S.
    Cardiovasc Hematol Disord Drug Targets; 2006 Jun 30; 6(2):71-6. PubMed ID: 16787192
    [Abstract] [Full Text] [Related]

  • 25. Buflomedil for intermittent claudication.
    de Backer TL, Bogaert M, Vander Stichele R.
    Cochrane Database Syst Rev; 2007 Oct 17; (4):CD000988. PubMed ID: 17943749
    [Abstract] [Full Text] [Related]

  • 26. Double-blind placebo-controlled trial of buflomedil in intermittent claudication.
    Fonseca V, Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Dandona P.
    Int J Clin Pharmacol Res; 1988 Oct 17; 8(5):377-81. PubMed ID: 3229875
    [Abstract] [Full Text] [Related]

  • 27. Buflomedil for intermittent claudication.
    de Backer TL, Bogaert M, Vander Stichele R.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD000988. PubMed ID: 18253982
    [Abstract] [Full Text] [Related]

  • 28. [Effect of drug therapy for chronic obliterating diseases of lower-limb arteries on the state of the microcirculatory bed].
    Uchkin IG, Zudin AM, Bagdasarian AG, Fedorovich AA.
    Angiol Sosud Khir; 2014 Jan 23; 20(2):27-36. PubMed ID: 24961324
    [Abstract] [Full Text] [Related]

  • 29. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G, Balzer K, Bisler H, Klüken N, Mahfoud Y, Müller-Wiefel H, Unkel B, Ziegler W.
    Dtsch Med Wochenschr; 1982 Dec 24; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract] [Full Text] [Related]

  • 30. Laser Doppler resting fluxes, flux motion frequencies and amplitudes at the skin of the dorsum of the foot in healthy young humans.
    Van den Brande P, Derde MP, Von Kemp K, Vanhulle A.
    Int Angiol; 1993 Mar 24; 12(1):40-6. PubMed ID: 8376910
    [Abstract] [Full Text] [Related]

  • 31. [Flowmetric, thermometric and rheologic studies in obliterating arterial diseases of the lower extremities treated with buflomedil].
    Dorigo B, Raspanti D, Trapani M, Albanese B, Cameli AM, Digiesi V.
    Minerva Med; 1985 Feb 25; 76(7):269-75. PubMed ID: 3974940
    [Abstract] [Full Text] [Related]

  • 32. Buflomedil for intermittent claudication.
    de Backer TL, Vander Stichele R.
    Cochrane Database Syst Rev; 2013 Mar 28; 2013(3):CD000988. PubMed ID: 23543509
    [Abstract] [Full Text] [Related]

  • 33. [Acral skin circulation following intra-arterial infusion of vasodilating substances in patients with intermittent claudication].
    Scheffler A, Rieger H.
    Med Klin (Munich); 1990 Jan 15; 85(1):1-5. PubMed ID: 2314351
    [Abstract] [Full Text] [Related]

  • 34. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
    J Am Coll Cardiol; 1998 Nov 15; 32(5):1336-44. PubMed ID: 9809945
    [Abstract] [Full Text] [Related]

  • 35. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
    Peters H, Kieser M, Hölscher U.
    Vasa; 1998 May 15; 27(2):106-10. PubMed ID: 9612115
    [Abstract] [Full Text] [Related]

  • 36. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
    Mozzi E, Chiurazzi D, Spinola A, Annoni F, Germiniani R.
    J Int Med Res; 1985 May 15; 13(6):317-21. PubMed ID: 4076530
    [Abstract] [Full Text] [Related]

  • 37. An experimental overview of a new vasoactive drug: buflomedil HCl.
    Dubourg A, Scamuffa RF.
    Angiology; 1981 Oct 15; 32(10):663-75. PubMed ID: 7034590
    [Abstract] [Full Text] [Related]

  • 38. Effects of monoionic and nonionic radiographic contrast media on cutaneous microcirculation in patients with peripheral arterial occlusive disease.
    Franzeck UK, Schalch I, Seiler Y, Schneider E, Bollinger A.
    Microvasc Res; 1995 Jul 15; 50(1):18-24. PubMed ID: 7476576
    [Abstract] [Full Text] [Related]

  • 39. Microcirculatory compensation to progressive atherosclerotic disease.
    Cisek PL, Eze AR, Comerota AJ, Kerr R, Brake B, Kelly P.
    Ann Vasc Surg; 1997 Jan 15; 11(1):49-53. PubMed ID: 9061139
    [Abstract] [Full Text] [Related]

  • 40. Clinical and microcirculatory effects of transcutaneous CO2 therapy in intermittent claudication. Randomized double-blind clinical trial with a parallel design.
    Fabry R, Monnet P, Schmidt J, Lusson JR, Carpentier PH, Baguet JC, Dubray C.
    Vasa; 2009 Aug 15; 38(3):213-24. PubMed ID: 19736632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.